GEN-MKT-18-7897-A
Aug 23, 2016 | Biopharma, Blogs | 0 comments
At ASMS this year, the newest version of BioPharmaView Software was released. This software simplifies the processing of biotherapeutic data for characterization and comparability which can dramatically improve your productivity. BioPharmaView 2.0 Software accelerates characterization and comparability studies and simplifies reporting, so you can make better decisions, faster.Try it today >
Everything You Need in One ViewGetting started with BioPharmaView software is easy. From the main window, you can input your assay information and save your batch processing parameters. You can also define the biotherapeutic sequence and choose from common post-translational modifications, or easily add custom modifications of interest.
Compare it and Share itWhen it comes time to report your results, BioPharmaView software provides you with comprehensive reports in multiple output formats. You’ll be able to quickly show the products that passed or failed your custom flagging criteria, and easily transfer your processed data export to electronic notebook applications.
Quick Look Intact Mass Comparability is Now a RealityThe hardest part of Intact Mass Analysis is processing the data and comparing biologic product characteristics. BioPharmaView Software makes it easy with one click batch processing, protein form matching, and automated ratio calculations for post translational modifications, including glycosylation. The multi-pane view in the main window allows you to see the processed and raw data from multiple samples side by side, so you can be confident about your comparability conclusions.
No Fear of Antibody Drug ConjugatesIntact analysis of antibody-drug conjugates (ADCs) can be challenging because of the size and complexity of the molecules. There’s no need to worry about your ADCs with automated drug-antibody ratio (DAR) calculation and visualization, as well as a simplified—yet highly accurate—view of protein deconvolution in BioPharmaView Software. Comparing ADC products is much easier when you can see drug load and DAR across multiple samples, so you’ll be clear on just what you’ve got—and how much.
Peptide Maps in a FlashComparison of peptide sequences across samples is much faster and easier than before in BioPharmaView Software. Everything you need to see for peptide map comparability is available in one view: from comprehensive sequence coverage and PTM ratios, to the raw MS/MS data you need to see to confirm modifications, BioPharmaView Software provides an easy to use dashboard for Peptide Mapping. At a glance, you can compare peptides, PTMs, PTM ratios and disulfide bond localization.
Low Level Modifications Can’t Hide from SWATH® AcquisitionWhen performing Peptide Mapping of biotherapeutics, you have to determine where post-translational modifications are. Using SWATH Acquisition and BioPharmaView Software processing, you can detect low level modifications—as well as confirm them in the high-resolution MS/MS spectra—all in a single run. Plus, automated calculation of PTM ratios means you can spend more time understanding your data, and less time crunching the numbers.
Where are the Disulfide Bonds?Localizing disulfide bonds is no easy task. But the algorithms in BioPharmaView software make quick work of defining the bond locations and presenting the high-resolution, annotated MS/MS spectra for confirmation.
Still not convinced to try it? Watch this video >Try it today >Or buy it today > Did you know there’s now a way you can upgrade/update your software as soon as new versions become available? Get the most from your solutions and troubleshooting tips and maximize the full potential of your lab >
Regulated laboratories are evolving faster than ever. New analytical modalities, higher sample throughput, increasing regulatory scrutiny, and leaner teams are reshaping how work gets done. At the same time, expectations for data integrity, standardization, and operational efficiency continue to increase complexity and/or scope. In this environment, LC-MS software is no longer simply an instrument control platform—it has become a critical part of a laboratory’s quality management system. The question is no longer whether your lab has changed, but whether your software has evolved to support the way regulated labs operate today, and if they are ready and able to meet the demands, they will face tomorrow.
Analyst software has long been a trusted foundation in regulated LC-MS laboratories—and for many, it still performs reliably today. But regulated environments are evolving faster than ever. As labs transition to Windows 11, strengthen cybersecurity policies, modernize IT infrastructure, and prepare for future compliance expectations, software decisions are no longer just about what works today—they’re about managing tomorrow’s risk. Analyst will not be supported on Windows 11. While some labs may continue operating in unsupported environments temporarily, the bigger question is: when that risk becomes reality, will your lab be reacting under pressure—or executing a planned mitigation strategy with confidence?
As regulatory scrutiny increases and detection requirements tighten, laboratories are facing a new question: How can TFA be measured reliably, sensitively, and at scale?
Posted by
You must be logged in to post a comment.
Share this post with your network